Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model

Antimicrob Agents Chemother. 2005 Sep;49(9):3977-9. doi: 10.1128/AAC.49.9.3977-3979.2005.

Abstract

Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium tuberculosis and treated for 8 weeks with four concentrations of moxifloxacin (0.125, 0.25, 0.50, and 1.0%) mixed into the diet had drug concentrations of 2.4, 4.1, 5.3, and 17.9 microg/ml, respectively, in blood. Selection of fluoroquinolone-resistant mutants occurred in all surviving mice.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Aza Compounds / therapeutic use*
  • Body Weight / drug effects
  • DNA Gyrase / genetics
  • DNA Primers
  • Diet
  • Drug Resistance, Bacterial
  • Eating
  • Female
  • Fluoroquinolones / pharmacology*
  • Mice
  • Mice, Inbred BALB C
  • Moxifloxacin
  • Mycobacterium tuberculosis / drug effects*
  • Quinolines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tuberculosis / drug therapy*
  • Tuberculosis / microbiology*

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • DNA Primers
  • Fluoroquinolones
  • Quinolines
  • DNA Gyrase
  • Moxifloxacin